Form 4: Organon & Co. CEO Kevin Ali Reports Stock Option Grant and RSU Vesting
SEC Form 4 Filing
CEO Kevin Ali reports the vesting of restricted stock units (RSUs) and the grant of stock options in Organon & Co.
Summary
- On March 31, 2025, Kevin Ali, CEO of Organon & Co., reported transactions involving Organon common stock.
- These transactions included the vesting of several tranches of Restricted Stock Units (RSUs) and the grant of new stock options.
- The vesting of RSUs resulted in the acquisition of shares, while a portion of shares were disposed of to cover tax obligations.
- Ali was granted 1,072,607 stock options exercisable in three equal installments starting March 31, 2026.
- He also received 218,267 new RSUs that will vest in three equal installments starting March 31, 2026.
- The reported transactions changed Ali's direct ownership of Organon common stock to 248,731.157 shares.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed neutrally to positively as they align management interests with shareholders. The sentiment is moderately positive due to the incentive structure.
Positives
- The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders.
- The vesting schedule of the options and RSUs encourages long-term commitment from the CEO.
Future Outlook
The document outlines future vesting dates for stock options and RSUs, indicating continued equity-based compensation for the CEO.
Industry Context
Equity-based compensation is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices for CEOs in publicly traded companies, including those in the pharmaceutical sector.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
- The vesting schedules described are typical, often spanning three to four years to encourage long-term performance.
Stakeholder Impact
- Shareholders: The vesting of RSUs and granting of stock options can impact the share price and overall shareholder value.
- Employees: Equity-based compensation can motivate employees and align their interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. |
| 03/31/2023 | RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. |
| 03/29/2024 | RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. |
| 03/28/2025 | Closing market price of Organon common stock was $14.51. |
| 03/31/2025 | Date of transactions: vesting of RSUs and grant of stock options. |
| 03/31/2026 | First vesting date for new stock options and RSUs. |
| 03/31/2027 | Second vesting date for new stock options and RSUs. |
| 03/31/2028 | Final vesting date for new stock options. |
| 04/02/2025 | Date of signature for the Form 4 filing. |
Keywords
Organon & Co., Kevin Ali, Form 4, RSU, Stock Options, Beneficial Ownership, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.